$Hims & Hers Health Inc.(HIMS)$ – Multiple Technical and Fundamental Red Flags Ahead of Current Breakdown
Price is down -28.65% MTD, but several warning signs had already emerged since early November.
These included VARW warning, a major support break aligning with the first YoY EPS deceleration since 2022, weakening price follow-through, and a loss of the 200-MA for the first time since 2023.
Don't let patience turns into denial in a losing position.
"Hims & Hers shares fall after BofA cuts price target to $21 and flags heightened FDA-related risks to its GLP-1 business. The company is halting sales of its compounded Wegovy pill following an FDA probe and faces a $Novo-Nordisk A/S(NVO)$ federal patent-infringement lawsuit over compounded Wegovy and Ozempic products."
Comments